Physician profile
Stephen J Moses
NPI 1003804600
$1,481.58
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.38 | 2019-2020 | |
| Janssen Biotech, INC. | $296.40 | 2019 | |
| Amgen INC. | $253.80 | 2019 | |
| Pfizer INC. | $125.47 | 2019 | |
| Ucb, INC. | $99.25 | 2019 | |
| Glaxosmithkline, LLC. | $55.42 | 2019 | |
| Celgene Corporation | $46.71 | 2019 | |
| Horizon Therapeutics Plc | $42.55 | 2019 | |
| Lilly USA, LLC | $39.06 | 2019 | |
| Pacira Therapeutics, INC. | $35.75 | 2019 | |
| Merck Sharp & Dohme LLC | $26.54 | 2019 | |
| Genentech USA, INC. | $12.25 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.